Consistent with this notion, a recent clinical trial with TNF-α antagonist in patients with treatment-resistant depression showed therapeutic effects only in the subsample of patients who had increased baseline inflammatory markers.48 Therefore, increased baseline inflammatory markers could be used to stratify patients in future trials evaluating the effectiveness of adjuvant anti-inflammatory treatment. The gene discussed is TNF; the disease is depressive symptom measurement.